Common Stock, Shares, Issued of LIPELLA PHARMACEUTICALS INC. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Summary
LIPELLA PHARMACEUTICALS INC. quarterly Common Stock, Shares, Issued in shares history and change rate from 31 Dec 2021 to 30 Sep 2025.
  • LIPELLA PHARMACEUTICALS INC. Common Stock, Shares, Issued for the quarter ending 30 Sep 2025 was 4,620,837, a 323% increase year-over-year.
Source SEC data
View on sec.gov
Common Stock, Shares, Issued, Quarterly (shares)
Common Stock, Shares, Issued, YoY Quarterly Change (%)

LIPELLA PHARMACEUTICALS INC. Quarterly Common Stock, Shares, Issued (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 4,620,837 +3,529,632 +323% 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 4,467,395 -3,138,241 -41% 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 2,548,811 -4,491,035 -64% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 1,208,919 +452,176 +60% 31 Dec 2024 10-Q 14 Nov 2025 2025 Q3
Q3 2024 1,091,205 -4,712,740 -81% 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 7,605,636 +1,861,691 +32% 30 Jun 2024 10-Q 13 Aug 2024 2024 Q2
Q1 2024 7,039,846 +1,295,901 +23% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 756,743 -4,987,213 -87% 31 Dec 2023 10-K 28 Mar 2025 2024 FY
Q3 2023 5,803,945 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 5,743,945 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 5,743,945 31 Mar 2023 10-Q 12 May 2023 2023 Q1
Q4 2022 5,743,956 +1,877,331 +49% 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q4 2021 3,866,625 31 Dec 2021 10-K 31 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.